{"name":"Galera Therapeutics","slug":"galera","ticker":"GRTX","exchange":"NASDAQ","domain":"galeratx.com","description":"Galera Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for various diseases. The company's pipeline includes several promising candidates, with a primary focus on oncology and cardiovascular diseases. Galera Therapeutics has a strong presence in the biotech industry, with a growing portfolio of products and partnerships. The company's mission is to improve patient outcomes through the development of novel therapeutics.","hq":"Malvern, PA","founded":0,"employees":"","ceo":"Mel Sorensen","sector":"Clinical-Stage Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$55M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":349000,"netIncome":149049000,"cash":6375000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Dextromethorphan HBr","genericName":"Dextromethorphan HBr","slug":"dextromethorphan-hbr","indication":"Cough suppression (OTC/marketed indication)","status":"marketed"},{"name":"GC4419 IV","genericName":"GC4419 IV","slug":"gc4419-iv","indication":"Other","status":"phase_1"},{"name":"GC4702 lipid suspension","genericName":"GC4702 lipid suspension","slug":"gc4702-lipid-suspension","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Dextromethorphan HBr","genericName":"Dextromethorphan HBr","slug":"dextromethorphan-hbr","phase":"marketed","mechanism":"Dextromethorphan HBr is a sigma-1 receptor agonist and NMDA receptor antagonist that reduces cough by suppressing the cough reflex center in the medulla.","indications":["Cough suppression (OTC/marketed indication)","Oral mucositis (potential pipeline indication under Galera development)"],"catalyst":""},{"name":"GC4419 IV","genericName":"GC4419 IV","slug":"gc4419-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GC4702 lipid suspension","genericName":"GC4702 lipid suspension","slug":"gc4702-lipid-suspension","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Galera Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for GC4419","summary":"Galera Therapeutics announced that the FDA has cleared the IND application for GC4419, a novel treatment for head and neck cancer.","drugName":"GC4419","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Galera Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Galera Therapeutics reported its third-quarter 2023 financial results, with a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-21","type":"deal","headline":"Galera Therapeutics Enters into Collaboration Agreement with Merck","summary":"Galera Therapeutics announced a collaboration agreement with Merck to develop and commercialize GC4419 for head and neck cancer.","drugName":"GC4419","sentiment":"positive"}],"realNews":[{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-09-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-05-15","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFAxa2RkbUpXbUZlOFk4NnhfYXpCTWhYcmJMa1Y5ZzYxdFZhYVRwcll0WDcyYXg0SXdiUl9UVVlaREd0NFV2TkFjMDk2aGExQzVIZ2c4?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"ADXS Stock Price, News & Analysis | Ayala Pharm - Stock Titan","headline":"ADXS Stock Price, News & Analysis | Ayala Pharm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOYlE1bDB1YnJCNjQ0QVBTMWdxb1ZwXzhLTFQ5ZHhEbWxWbnF1U2g1OGFydDlWYW1Pb1I2WklXdzNXZkhSSmFCUGVEX3ZWemg3VmhoSXd6WlY3X3JqZHpLYnZGY3JQWVdKOEcybWQzRHhyamFDSDJBckcxYngyd3hTS1kza0RqbXR2SVR2dnkyOGZWQ0ZXVzV0bXpzcF9UenFvRmFVQnlZU3NuaHlEcG10SHY0Z0pxOG1rdjQ2WGpSZnAxYWFFQjBENkZwNHMxc190S1dNdGE2Y3ZlZ21fVWV2OTJtX2NSaEd5Vm1nLTBpMGpsRnRnVFVHNmRNVUZ5NkhvX2pXaXlDQ0wwckEwR2c?oc=5","date":"2025-04-09","type":"pipeline","source":"Business Wire","summary":"Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire","headline":"Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Dire","sentiment":"neutral"},{"date":"2025-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1WdDNaMGhBeFlNMklYTnBQNm1HSUNhRWVURWZ5Qjd0eUxWQm0tQi1NNmQ4a1F5cGxpVTlUZUJ2MGwzRjI5bFFjYVBRaHd1UWpvM216RTVwNl81U2hsT3NZR2VzSjFyTUVKZ1RsU3F5ckNOQ2hNRWY4eEZnRQ?oc=5","date":"2025-03-31","type":"earnings","source":"qz.com","summary":"Galera Therapeutics Inc. (GRTX) reports earnings - qz.com","headline":"Galera Therapeutics Inc. (GRTX) reports earnings","sentiment":"neutral"},{"date":"2025-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_1":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Clovis Oncology","AstraZeneca","Bayer"],"therapeuticFocus":["Oncology","Cardiovascular Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":349000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":149049000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":6375000,"cashHistory":[],"totalAssets":7196000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}